Perospirone: Sumitomo Pharmaceuticals

Current Opinion in Investigational Drugs

Volumn 3, Issue 1, 2002, Pages 121-129

  De Paulis, Tomas ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BM 13859; CLOSPIPRAMINE; CLOZAPINE; DIAZEPAM; DOPAMINE 2 RECEPTOR BLOCKING AGENT; HALOPERIDOL; ILOPERIDONE; IMIPRAMINE; LURASIDONE; OLANZAPINE; PEROSPIRONE; REMOXIPRIDE; RISPERIDAL; RISPERIDONE; SEROTONIN 2A ANTAGONIST; SULPIRIDE; TANDOSPIRONE; TIOSPIRONE; UNCLASSIFIED DRUG; ZIPRASIDONE; ZOTEPINE; DOPAMINE RECEPTOR BLOCKING AGENT; INDOLE DERIVATIVE; SEROTONIN ANTAGONIST; THIAZOLE DERIVATIVE;

CLINICAL TRIAL; DOPAMINERGIC ACTIVITY; DOSE RESPONSE; DRUG APPROVAL; DRUG COST; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SYNTHESIS; DRUG TOLERABILITY; EXPERIMENTAL MODEL; EXTRAPYRAMIDAL SYMPTOM; HUMAN; NONHUMAN; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; STRUCTURE ACTIVITY RELATION; TOXICITY TESTING; ANIMAL; CHEMISTRY; METHODOLOGY; PHARMACEUTICS; STATISTICS;

ANIMAL; CLINICAL TRIALS; DOPAMINE ANTAGONISTS; HUMAN; INDOLES; SCHIZOPHRENIA; SEROTONIN ANTAGONISTS; TECHNOLOGY, PHARMACEUTICAL; THIAZOLES; ANIMALS; HUMANS;

EID: 0035985640     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. Binding profile of SM-9018, a novel antipsychotic candidate
2. Pharmacological actions of SM-9018, a new neuroleptic drug with both potent 5-hydroxytryptamine-2 and dopamine-2 antagonistic actions
3. 2 receptor antagonists: Potential atypical antipsychotic agents
4. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors
5. Effects of SM-9018, a potential atypical neuroleptic, on the central monoaminergic system in rats
6. Carbon-14 labeling of a succinimide derivative, SM-9018: A novel antipsychotic drug
7. 2 receptor occupancy
8. Effects of chronic treatments with SM-9018, a potential atypical neuroleptic, on behavioral dopaminergic and serotonergic sensitivites in rats
9. 4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs
10. 2 receptor antagonist, using the mouse pole test
11. Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin-2 and dopamine-2 receptors
12. In vitro receptor binding and in vivo receptor occupancy in rat and guinea pig brain: Risperidone compared with antipsychotics hitherto used
13. Succinimide derivatives. II. Synthesis and antipsychotic activity of N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-1,2-cis-cyclohexanedicarb oximide (SM-9018) and related compounds
14. 4 receptors
15. Serotonin-dopamine antagonists and treatment of negative symptoms
16. 3H]acetylcholine release from rat striatal slices
17. Evaluation of perospirone (SM-9018), a novel serotonin-2 and dopamine-2 receptor antagonist, and other antipsychotics in the conditioned fear stress-induced freezing behavior model in rats
18. Effects of typical and atypical antipsychotic drugs on freezing behavior induced by conditioned fear
19. 4 receptors in CHO cells
20. 2 receptor blocking activity
21. Contrasting effects of SM-9018, a potential atypical antipsychotic, and haloperidol on c-fos mRNA expression in the rat striatum
22. 2 antagonist, on dopamine and 5-HT receptors in rats
23. 2 antagonists: A concept for the treatment of schizophrenia
24. 2 receptor interaction in the atypical antipsychotic action of the novel succinamide derivative, perospirone
25. Long-term treatment of a new atypical neuroleptic, SM-9018 on patients with schizophrenia
26. Effects of perospirone, a novel antipsychotic agent, on the dopaminergic neurons in the rat ventral tegmental area
27. 2A receptors by novel antipsychotic drug, SM-9018 and its metabolite, in rat brain
28. Atypical antipsychotics. Part I: Pharmacology, pharmacokinetics, and efficacy
29. Recent advances in potential atypical antipsychotics: Past, present and future hopes - Preclinical and clinical considerations
30. Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs
31. Clinical evaluation of perospirone hydrochloride (SM-9018) in fine granule form in the treatment of schizophrenic patients
32. Biotransformation of post-clozapine antipsychotics. Pharmacological implications
33. 2 receptor antagonist, on Fos protein expression in the rat forebrain
34. Anxiolytic-like effects of perospirone, a novel serotonin-2 and dopamine-2 antagonist (SDA)-type antipsychotic agent
35. Perospirone hydrochloride: Antipsychotic
36. 3H]perospirone- binding sites in rat brain
37. 2A receptors in the rat brain
38. In-vivo assessment of 5-HT(2A) and 5-HT(2C) antagonistic properties of newer antipsychotics
39. Serotonin-2C receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: A combined dialysis and electrophysiological analysis in the rat
40. 2 receptors by dopamine in schizophrenia
41. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method
42. 2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia
43. 2A antagonists on inherited catalepsy in rats
44. Serotonergic involvement in haloperidol-induced catalepsy
45. 2 receptors
46. Recent advances in atypical antipsychotics
47. Sumitomo, Yoshitomi Yakuhin to co-promote Sumitomo's Perispirone
48. Sumitomo to focus on market for psychotropic drugs
49. CAPC's Executive Committee recommends approval of 16 active ingredients
50. Peak sales of 5 new drugs expected to exceed Yen 10 billion: Chuikyo
51. New drugs to be added to the NIH drug price list on February 2, 2001
52. Sumitomo revises sales for 2002 upward to Yen 150 billion: President Yokotsuka
53. Price of Seroquel is 4 times higher than Lullan
54. Perospirone
55. Improving the treatment of schizophrenia: Focus on serotonin (5-HT)(1A) receptors
56. Pharmacological characteristics of perospirone hydrochloride, a novel antipsychotic agent
57. Pricing organization accepts Eli Lilly Japan's objection
58. 2C receptor inverse agonist with improved anxiolytic profile: Lack of tolerance and withdrawal anxiety
59. Perospirone: A viewpoint
60. The pharmacology and toxicology of atypical antipsychotic agents
61. Synthesis and biological activity of the putative metabolites of the atypical antipsychotic agent tiospirone
62. 2C receptors: A parallel phosphatidylinositol and calcium accumulation comparison with clozapine and haloperidol
63. SB 242 084, a selective serotonin-2C receptor antagonist, increases dopaminergic transmission in the mesolimbic system
64. The new generation of antipsychotic drugs: How atypical are they?
65. 2C receptors
66. Dose selection and comparator drugs in schizophrenia research
67. 2 receptors. Implications for atypical antipsychotic action
68. 2 receptor explain the action of atypical antipsychotics?: A new hypothesis
69. Metabolism of the antipsychotic drug tiospirone in humans
70. Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding
71. Antipsychotic drugs: Importance of dopamine receptors for mechanisms of therapeutic actions and side effects
72. Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: Implications for antipsychotic drug treatment
73. Synthesis and biological evaluation of 1-(1,2-benzisothiazol-3-yl)- and (1,2-benzisooxazol-3-yl)piperazine derivatives as potential antipsychotic agents
74. Phase I study of perospirone HCl (SM-9018)
75. CNS pharmacological actions of the major metabolites of perospirone hydrochloride
76. Toxicity studies with single-dose and repeated-dose oral administration of SM-9018 in monkeys
77. Early phase II study of a new antipsychotic, perospirone HCl (SM-9018), on schizophrenia
78. Clinical evaluation of a new antipsychotic, perospirone HCl, on schizophrenia: Late-phase II study
79. Clinical evaluation of a new antipsychotic, perospirone HCl, on schizophrenia: A study of long-term administration
80. Clinical evaluation of a new antipsychotic, perospirone HCl, on schizophrenia: A comparative double-blind study with mosapramine HCl
81. Acute toxicity of SM-9018 in mice and rats
82. Clinical evaluation of a new antipsychotic, perospirone HCl, on schizophrenia: A comparative double-blind study with haloperidol
83. 2 antagonist in healthy male volunteers
84. The effect of the antipsychotic drug mosapramine on the expression of Fos protein in the rat brain. Comparison with haloperidol, clozapine and risperidone